FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:690-694 September 2, 1993 Number 10 Next

	Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The proto-oncogene bcl-2 encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied bcl-2 expression in patients with non-small-cell lung carcinoma and correlated this phenomenon with survival.

Methods Immunochemical analysis with a monoclonal antibody specific for bcl-2 was used to detect the protein in tumor samples from 122 patients undergoing surgery for squamous-cell carcinoma (80 patients) or adenocarcinoma (42 patients). The possibility that bcl-2 expression correlated with survival was investigated with use of the log-rank test, hazard ratios, and their confidence intervals.

Results We detected bcl-2 protein in 25 percent of squamous-cell carcinomas (20 of 80) and 12 percent of adenocarcinomas (5 of 42). In adjacent normal respiratory epithelium, bcl-2 was expressed only in basal cells. Survival at five years was higher among patients with bcl-2-positive tumors, both in the group as a whole (P<0.1) and in the group with squamous-cell carcinoma (P<0.02). Patients 60 years of age or older who had bcl-2-positive tumors had the best prognoses, both in the group as a whole (P<0.02) and in the group with squamous-cell carcinoma (P<0.01).

Conclusions The proto-oncogene bcl-2 is abnormally expressed in some lung carcinomas, and its expression may have prognostic importance.

Source Information

From the Leukaemia Research Fund Immunodiagnostics Unit (F.P., D.Y.M.), the Nuffield Department of Pathology (H.T., I.K., M.F.T., M.S.D., K.C.G.), the University Data Centre (C.B.P.), and the Molecular Oncology Laboratory (Imperial Cancer Research Fund) (A.H.), John Radcliffe Hospital, Oxford, United Kingdom.

Address reprint requests to Dr. Pezzella at the Leukaemia Research Fund Immunodiagnostics Unit, Level 1, Maternity Block, John Radcliffe Hospital, OX3 9DU, Oxford, United Kingdom.

Full Text of this Article

Related Letters:

bcl-2 and Prognosis in Non-Small-Cell Lung Carcinoma
Gaffney E. F., O'Neill A. J., Staunton M. J., Pezzella F.
Extract | Full Text  
N Engl J Med 1994; 330:1757-1758, Jun 16, 1994. Correspondence

Acute Monoarthritis
Canoso J. J., Schumacher H. R., Baker D. G.
Extract | Full Text  
N Engl J Med 1994; 330:221-222, Jan 20, 1994. Correspondence

This article has been cited by other articles:

• Liu, G., Kolesar, J., McNeel, D. G., Leith, C., Schell, K., Eickhoff, J., Lee, F., Traynor, A., Marnocha, R., Alberti, D., Zwiebel, J., Wilding, G. (2008). A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 14: 2732-2739 [Abstract] [Full Text]  
• Choi, S., Myers, J.N. (2008). Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. J. Dent. Res. 87: 14-32 [Abstract] [Full Text]  
• Trere, D, Montanaro, L, Ceccarelli, C, Barbieri, S, Cavrini, G, Santini, D, Taffurelli, M, Derenzini, M (2007). Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol 18: 1004-1014 [Abstract] [Full Text]  
• Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., Bepler, G. (2007). DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer. NEJM 356: 800-808 [Abstract] [Full Text]  
• Maluf, F., Cordon-Cardo, C, Verbel, D., Satagopan, J., Boyle, M., Herr, H, Bajorin, D. (2006). Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol 17: 1677-1686 [Abstract] [Full Text]  
• Dai, J., Chen, D., Jones, R. A., Hurley, L. H., Yang, D. (2006). NMR solution structure of the major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids Res 34: 5133-5144 [Abstract] [Full Text]  
• Pajares, M. J., Zudaire, I., Lozano, M. D., Agorreta, J., Bastarrika, G., Torre, W., Remirez, A., Pio, R., Zulueta, J. J., Montuenga, L. M. (2006). Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.. Cancer Epidemiol. Biomarkers Prev. 15: 373-380 [Abstract] [Full Text]  
• Vigano, P., Somigliana, E., Chiodo, I., Abbiati, A., Vercellini, P. (2006). Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 12: 77-89 [Abstract] [Full Text]  
• Onn, A., Choe, D. H., Herbst, R. S., Correa, A. M., Munden, R. F., Truong, M. T., Vaporciyan, A. A., Isobe, T., Gilcrease, M. Z., Marom, E. M. (2005). Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. Radiology 237: 342-347 [Abstract] [Full Text]  
• Cheng, T.-L., Chang, M.-Y., Huang, S.-Y., Sheu, C.-C., Kao, E.-L., Cheng, Y.-J., Chong, I.-W. (2005). Overexpression of Circulating c-Met Messenger RNA Is Significantly Correlated With Nodal Stage and Early Recurrence in Non-Small Cell Lung Cancer. Chest 128: 1453-1460 [Abstract] [Full Text]  
• Shah, A., Swain, W. A., Richardson, D., Edwards, J., Stewart, D. J., Richardson, C. M., Swinson, D. E.B., Patel, D., Jones, J. L., O'Byrne, K. J. (2005). Phospho-Akt Expression Is Associated with a Favorable Outcome in Non-Small Cell Lung Cancer. Clin. Cancer Res. 11: 2930-2936 [Abstract] [Full Text]  
• Meuwissen, R., Berns, A. (2005). Mouse models for human lung cancer. Genes Dev. 19: 643-664 [Abstract] [Full Text]  
• Simon, G. R., Sharma, S., Cantor, A., Smith, P., Bepler, G. (2005). ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer. Chest 127: 978-983 [Abstract] [Full Text]  
• Marshall, J., Chen, H., Yang, D., Figueira, M., Bouker, K. B., Ling, Y., Lippman, M., Frankel, S. R., Hayes, D. F. (2004). A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 15: 1274-1283 [Abstract] [Full Text]  
• Tsao, A. S., Kim, E. S., Hong, W. K. (2004). Chemoprevention of Cancer. CA Cancer J Clin 54: 150-180 [Abstract] [Full Text]  
• Mazieres, J., Antonia, T., Daste, G., Muro-Cacho, C., Berchery, D., Tillement, V., Pradines, A., Sebti, S., Favre, G. (2004). Loss of RhoB Expression in Human Lung Cancer Progression. Clin. Cancer Res. 10: 2742-2750 [Abstract] [Full Text]  
• Bodner, K., Bodner-Adler, B., Kimberger, O., Czerwenka, K., Mayerhofer, K. (2004). Bcl-2 Receptor Expression in Patients With Uterine Smooth Muscle Tumors: An Immunohistochemical Analysis Comparing Leiomyoma, Uterine Smooth Muscle Tumor of Uncertain Malignant Potential, and Leiomyosarcoma. Reproductive Sciences 11: 187-191 [Abstract]  
• Onn, A., Correa, A. M., Gilcrease, M., Isobe, T., Massarelli, E., Bucana, C. D., O'Reilly, M. S., Hong, W. K., Fidler, I. J., Putnam, J. B., Herbst, R. S. (2004). Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clin. Cancer Res. 10: 136-143 [Abstract] [Full Text]  
• Allal, A. S., Waelchli, L., Brundler, M.-A. (2003). Prognostic Value of Apoptosis-Regulating Protein Expression in Anal Squamous Cell Carcinoma. Clin. Cancer Res. 9: 6489-6496 [Abstract] [Full Text]  
• Poleri, C., Morero, J. L., Nieva, B., Vazquez, M. F., Rodriguez, C., de Titto, E., Rosenberg, M. (2003). Risk of Recurrence in Patients With Surgically Resected Stage I Non-small Cell Lung Carcinoma: Histopathologic and Immunohistochemical Analysis. Chest 123: 1858-1867 [Abstract] [Full Text]  
• Jeanmart, M., Lantuejoul, S., Fievet, F., Moro, D., Sturm, N., Brambilla, C., Brambilla, E. (2003). Value of Immunohistochemical Markers in Preinvasive Bronchial Lesions in Risk Assessment of Lung Cancer. Clin. Cancer Res. 9: 2195-2203 [Abstract] [Full Text]  
• Cheema, S. K., Mishra, S. K., Rangnekar, V. M., Tari, A. M., Kumar, R., Lopez-Berestein, G. (2003). Par-4 Transcriptionally Regulates Bcl-2 through a WT1-binding Site on the bcl-2 Promoter. J. Biol. Chem. 278: 19995-20005 [Abstract] [Full Text]  
• van de Wouw, A. J., Jansen, R. L. H., Speel, E. J. M., Hillen, H. F. P. (2003). The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 14: 191-196 [Abstract] [Full Text]  
• Brambilla, C., Fievet, F., Jeanmart, M., de Fraipont, F., Lantuejoul, S., Frappat, V., Ferretti, G., Brichon, P.Y., Moro-Sibilot, D. (2003). Early detection of lung cancer: role of biomarkers. Eur Respir J 21: 36S-44s [Abstract] [Full Text]  
• Lai, R.-S., Wang, J.-S., Hsu, H.-K., Chang, H.-C., Lin, C.-H., Lin, M.-H. (2002). Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung Cancer. Jpn J Clin Oncol 32: 393-397 [Abstract] [Full Text]  
• Morris, M. J., Tong, W. P., Cordon-Cardo, C., Drobnjak, M., Kelly, W. K., Slovin, S. F., Terry, K. L., Siedlecki, K., Swanson, P., Rafi, M., DiPaola, R. S., Rosen, N., Scher, H. I. (2002). Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer. Clin. Cancer Res. 8: 679-683 [Abstract] [Full Text]  
• Huisman, C., Ferreira, C. G., Broker, L. E., Rodriguez, J. A., Smit, E. F., Postmus, P. E., Kruyt, F. A. E., Giaccone, G. (2002). Paclitaxel Triggers Cell Death Primarily via Caspase-independent Routes in the Non-Small Cell Lung Cancer Cell Line NCI-H460. Clin. Cancer Res. 8: 596-606 [Abstract] [Full Text]  
• Kakolyris, S., Giatromanolaki, A., Koukourakis, M., Powis, G., Souglakos, J., Sivridis, E., Georgoulias, V., Gatter, K. C., Harris, A. L. (2001). Thioredoxin Expression Is Associated with Lymph Node Status and Prognosis in Early Operable Non-Small Cell Lung Cancer. Clin. Cancer Res. 7: 3087-3091 [Abstract] [Full Text]  
• Meterissian, S. H., Kontogiannea, M., Al-Sowaidi, M., Linjawi, A., Halwani, F., Jamison, B., Edwardes, M. (2001). Bcl-2 Is a Useful Prognostic Marker in Dukes' B Colon Cancer. Ann. Surg. Oncol. 8: 533-537 [Abstract] [Full Text]  
• Kim, N. K., Park, J. K., Lee, K. Y., Yang, W. I., Yun, S. H., Sung, J., Min, J. S. (2001). p53, BCL-2, and Ki-67 Expression According to Tumor Response After Concurrent Chemoradiotherapy for Advanced Rectal Cancer. Ann. Surg. Oncol. 8: 418-424 [Abstract] [Full Text]  
• Rossiter, H., Beissert, S., Mayer, C., Schön, M. P., Wienrich, B. G., Tschachler, E., Kupper, T. S. (2001). Targeted Expression of bcl-2 to Murine Basal Epidermal Keratinocytes Results in Paradoxical Retardation of Ultraviolet- and Chemical-induced Tumorigenesis. Cancer Res. 61: 3619-3626 [Abstract] [Full Text]  
• Laudanski, J., Niklinska, W., Burzykowski, T., Chyczewski, L., Niklinski, J. (2001). Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer. Eur Respir J 17: 660-666 [Abstract] [Full Text]  
• Khuri, F. R., Wu, H., Lee, J. J., Kemp, B. L., Lotan, R., Lippman, S. M., Feng, L., Hong, W. K., Xu, X.-C. (2001). Cyclooxygenase-2 Overexpression Is a Marker of Poor Prognosis in Stage I Non-Small Cell Lung Cancer. Clin. Cancer Res. 7: 861-867 [Abstract] [Full Text]  
• Kerr, K M (2001). Pulmonary preinvasive neoplasia. J. Clin. Pathol. 54: 257-271 [Abstract] [Full Text]  
• Gautschi, O., Tschopp, S., Olie, R. A., Leech, S. H., Simoes-Wust, A. P., Ziegler, A., Baumann, B., Odermatt, B., Hall, J., Stahel, R. A., Zangemeister-Wittke, U. (2001). Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins. JNCI J Natl Cancer Inst 93: 463-471 [Abstract] [Full Text]  
• Perez-Soler, R., Kemp, B., Wu, Q. P., Mao, L., Gomez, J., Zeleniuch-Jacquotte, A., Yee, H., Lee, J. S., Jagirdar, J., Ling, Y. H. (2000). Response and Determinants of Sensitivity to Paclitaxel in Human Non-Small Cell Lung Cancer Tumors Heterotransplanted in Nude Mice. Clin. Cancer Res. 6: 4932-4938 [Abstract] [Full Text]  
• Tang, X., Khuri, F. R., Lee, J. J., Kemp, B. L., Liu, D., Hong, W. K., Mao, L. (2000). Hypermethylation of the Death-Associated Protein (DAP) Kinase Promoter and Aggressiveness in Stage I Non-Small-Cell Lung Cancer. JNCI J Natl Cancer Inst 92: 1511-1516 [Abstract] [Full Text]  
• Khuri, F. R., Lotan, R., Kemp, B. L., Lippman, S. M., Wu, H., Feng, L., Lee, J. J., Cooksley, C. S., Parr, B., Chang, E., Walsh, G. L., Lee, J. S., Hong, W. K., Xu, X.-C. (2000). Retinoic Acid Receptor-Beta as a Prognostic Indicator in Stage I Non-Small-Cell Lung Cancer. JCO 18: 2798-2804 [Abstract] [Full Text]  
• Ohmura, Y., Aoe, M., Andou, A., Shimizu, N. (2000). Telomerase Activity and Bcl-2 Expression in Non-Small Cell Lung Cancer. Clin. Cancer Res. 6: 2980-2987 [Abstract] [Full Text]  
• Konopleva, M., Tari, A. M., Estrov, Z., Harris, D., Xie, Z., Zhao, S., Lopez-Berestein, G., Andreeff, M. (2000). Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95: 3929-3938 [Abstract] [Full Text]  
• Renner, S., Weisz, J., Krajewski, S., Krajewska, M., Reed, J. C., Lichtenstein, A. (2000). Expression of BAX in Plasma Cell Dyscrasias. Clin. Cancer Res. 6: 2371-2380 [Abstract] [Full Text]  
• Herbst, R. S., Yano, S., Kuniyasu, H., Khuri, F. R., Bucana, C. D., Guo, F., Liu, D., Kemp, B., Lee, J. J., Hong, W. K., Fidler, I. J. (2000). Differential Expression of E-cadherin and Type IV Collagenase Genes Predicts Outcome in Patients with Stage I Non-Small Cell Lung Carcinoma. Clin. Cancer Res. 6: 790-797 [Abstract] [Full Text]  
• Moldvay, J., Scheid, P., Wild, P., Nabil, K., Siat, J., Borrelly, J., Marie, B., Farré, G., Labib, T., Pottier, G., Sesboüé, R., Bronner, C., Vignaud, J.-M., Martinet, Y., Martinet, N. (2000). Predictive Survival Markers in Patients with Surgically Resected Non-Small Cell Lung Carcinoma. Clin. Cancer Res. 6: 1125-1134 [Abstract] [Full Text]  
• Chan, W.-Y., Cheung, K.-K., Schorge, J. O., Huang, L.-W., Welch, W. R., Bell, D. A., Berkowitz, R. S., Mok, S. C. (2000). Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers. Am. J. Pathol. 156: 409-417 [Abstract] [Full Text]  
• Fong, K. M., Sekido, Y., Minna, J. D. (1999). MOLECULAR PATHOGENESIS OF LUNG CANCER. J. Thorac. Cardiovasc. Surg. 118: 1136-1152 [Abstract] [Full Text]  
• Arnold, S. M., Young, A. B., Munn, R. K., Patchell, R. A., Nanayakkara, N., Markesbery, W. R. (1999). Expression of p53, bcl-2, E-Cadherin, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 in Paired Primary Tumors and Brain Metastasis. Clin. Cancer Res. 5: 4028-4033 [Abstract] [Full Text]  
• Drenou, B., Blancheteau, V., Burgess, D. H., Fauchet, R., Charron, D. J., Mooney, N. A. (1999). A Caspase-Independent Pathway of MHC Class II Antigen-Mediated Apoptosis of Human B Lymphocytes. J. Immunol. 163: 4115-4124 [Abstract] [Full Text]  
• Reed, J. C. (1999). Dysregulation of Apoptosis in Cancer. JCO 17: 2941-2941 [Abstract] [Full Text]  
• Huang, C.-l., Kohno, N., Inufusa, H., Kodama, K., Taki, T., Miyake, M. (1999). Overexpression of bax Associated with Mutations in the Loop-Sheet-Helix Motif of p53. Am. J. Pathol. 155: 955-965 [Abstract] [Full Text]  
• Baekelandt, M., Kristensen, G. B., Nesland, J. M., Trope, C. G., Holm, R. (1999). Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian Cancer. JCO 17: 2061-2061 [Abstract] [Full Text]  
• Hogarth, L. A., Hall, A. G. (1999). Increased BAX Expression Is Associated With an Increased Risk of Relapse in Childhood Acute Lymphocytic Leukemia. Blood 93: 2671-2678 [Abstract] [Full Text]  
• D'Amico, MD, T. A., Massey, MD, M., Herndon II, PhD, J. E., Moore, M.-B., Harpole, D. H. Jr (1999). A BIOLOGIC RISK MODEL FOR STAGE I LUNG CANCER: IMMUNOHISTOCHEMICAL ANALYSIS OF 408 PATIENTS WITH THE USE OF TEN MOLECULAR MARKERS. J. Thorac. Cardiovasc. Surg. 117: 736-743 [Abstract] [Full Text]  
• Homma, A., Furuta, Y., Oridate, N., Nakano, Y., Kohashi, G., Yagi, K., Nagahashi, T., Fukuda, S., Inoue, K., Inuyama, Y. (1999). Prognostic Significance of Clinical Parameters and Biological Markers in Patients with Squamous Cell Carcinoma of the Head and Neck Treated with Concurrent Chemoradiotherapy. Clin. Cancer Res. 5: 801-806 [Abstract] [Full Text]  
• Waalkes, M. P., Diwan, B. A. (1999). Cadmium-induced inhibition of the growth and metastasis of human lung carcinoma xenografts: role of apoptosis. Carcinogenesis 20: 65-70 [Abstract] [Full Text]  
• Roland, M, Rudd, R M (1998). Genetics and pulmonary medicine bullet  7: Somatic mutations in the development of lung cancer. Thorax 53: 979-983 [Full Text]  
• Soini, Y., Paakko, P., Lehto, V-P. (1998). Histopathological Evaluation of Apoptosis in Cancer. Am. J. Pathol. 153: 1041-1053 [Full Text]  
• Ilyas, M, Hao, X-P, Wilkinson, K, Tomlinson, I P M, Abbasi, A M, Forbes, A, Bodmer, W F, Talbot, I C (1998). Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 43: 383-387 [Abstract] [Full Text]  
• Friess, H, Lu, Z, Graber, H U, Zimmermann, A, Adler, G, Korc, M, Schmid, R M, Buchler, M W (1998). bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421 [Abstract] [Full Text]  
• Eissa, S., Seada, L. S. (1998). Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry. Clin. Chem. 44: 1423-1429 [Abstract] [Full Text]  
• Tesfaigzi, J., Hotchkiss, J. A., Harkema, J. R. (1998). Expression of the Bcl-2 Protein in Nasal Epithelia of F344/N Rats during Mucous Cell Metaplasia and Remodeling. Am. J. Respir. Cell Mol. Bio. 18: 794-799 [Abstract] [Full Text]  
• Offen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., Melamed, E., Bernard, R., Bernard, O. (1998). Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA 95: 5789-5794 [Abstract] [Full Text]  
• GREATENS, T. M., NIEHANS, G. A., RUBINS, J. B., JESSURUN, J., KRATZKE, R. A., MADDAUS, M. A., NIEWOEHNER, D. E. (1998). Do Molecular Markers Predict Survival in Non-Small-Cell Lung Cancer?. Am. J. Respir. Crit. Care Med. 157: 1093-1097 [Abstract] [Full Text]  
• Findley, H. W., Gu, L., Yeager, A. M., Zhou, M. (1997). Expression and Regulation of Bcl-2, Bcl-xl, and Bax Correlate With p53 Status and Sensitivity to Apoptosis in Childhood Acute Lymphoblastic Leukemia. Blood 89: 2986-2993 [Abstract] [Full Text]  
• Nesbitt, J. C., Putnam, J. B. Jr, Walsh, G. L., Roth, J. A., Mountain, C. F. (1995). Survival in Early-Stage Non--Small Cell Lung Cancer. Ann. Thorac. Surg. 60: 466-472 [Abstract] [Full Text]  
• Merritt, A., Potten, C., Watson, A., Loh, D., Nakayama, K, Nakayama, K, Hickman, J. (1995). Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J. Cell Sci. 108: 2261-2271 [Abstract]  
• Gaffney, E. F., O'Neill, A. J., Staunton, M. J., Pezzella, F. (1994). bcl-2 and Prognosis in Non-Small-Cell Lung Carcinoma. NEJM 330: 1757-1758 [Full Text]  
• Katz, H. R., Pezzella, F., Harris, A., Gatter, K. C. (1994). bcl-2 Protein in Non-Small-Cell Lung Carcinoma. NEJM 330: 221-221 [Full Text]